VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the potential of its nucleosome quantification technology.
Multiple studies have shown that Volition's Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations.
Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. Sepsis remains a leading cause of death worldwide, and early, accurate diagnosis is critical for improving patient outcomes. Current diagnostic methods often fall short in distinguishing sepsis from other inflammatory conditions, leading to delayed or inappropriate treatment.
The Nu.Q NETs assay measures circulating nucleosomes, specifically the H3.1 variant, which is released during NETosis—a form of cell death that plays a key role in sepsis and other inflammatory diseases. By providing a rapid, cost-effective blood test, Volition aims to address a significant unmet need in critical care.
The implications of this announcement are substantial for the medical community and patients. If widely adopted, the Nu.Q H3.1 test could enable clinicians to identify sepsis earlier, tailor treatments to individual patients, and potentially reduce mortality rates. It could also help in monitoring disease progression and response to therapy, thereby optimizing resource utilization in intensive care units.
Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For further information, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/2IH3m.
